FDA发布拟议规则:NAC可望重新作为膳食补充剂合法销售,公众意见征集60天

美国食品药品监管局(FDA)11月16日发布拟议规则,拟推翻此前把N-乙酰-L-半胱氨酸(N-acetyl-L-cysteine,简称NAC)排除在「膳食补充剂」定义之外的做法。规则如获最终通过,含NAC的产品只要不违反《联邦食品、药品和化妆品法》(FD&C Act),就可以作为膳食补充剂合法销售。拟议规则即日起在《联邦公报》征集公众意见,为期60天。
FDA在说明中回顾,2022年3月,该局在回复两份公民请愿时曾认定,含NAC的产品不能算作膳食补充剂。此次拟议规则将新设一项名为「未被排除在膳食补充剂定义之外的膳食成分」的法规,为原本会被排除的成分提供合法用于膳食补充剂的通道。FDA表示,这是该局首次动用膳食补充剂定义中排除条款所赋予的规则制定权,NAC将成为这项新法规下首个列入的成分。
FDA表示,该局经过全面审查,未发现NAC用作或用于膳食补充剂存在安全问题;含NAC并标示为膳食补充剂的产品已在美国销售30多年,消费者一直有获取这类产品的需求。2022年8月,FDA曾发布行业最终指南,表示将对部分标示为膳食补充剂的含NAC产品暂时行使执法裁量。FDA称,在规则制定程序走完之前,这一执法裁量政策将继续执行。
FDA表示,这项行动如获最终通过,将属于特朗普总统第14192号行政令「通过放松监管释放繁荣」项下的放松监管行动。公众意见提交方式见《联邦公报》刊登的拟议规则通知。
(来源:美国食品药品监管局)
FDA Issues Proposed Rule to Allow NAC in Dietary Supplements, Opens 60-Day Comment Period
The U.S. Food and Drug Administration (FDA) on November 16 issued a proposed rule that, if finalized, would reverse the exclusion of N-acetyl-L-cysteine (NAC) from the definition of "dietary supplement." Under the proposal, NAC-containing products could be lawfully marketed as dietary supplements, provided they are not otherwise in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The proposed rule is open for public comment for 60 days through the Federal Register.
The FDA noted that in a March 2022 response to two citizen petitions, it had concluded that NAC-containing products cannot be dietary supplements. The proposed rule would establish a new regulation, titled "Dietary Ingredients Not Excluded from the Dietary Supplement Definition," to provide for the lawful use of certain ingredients that would otherwise be excluded from the definition. The agency said this is its first use of the rulemaking authority described in the exclusion provision of the dietary supplement definition, and NAC would be the first ingredient listed under the new regulation.
The FDA said it undertook a comprehensive review and did not identify any safety concerns with the use of NAC in or as a dietary supplement. NAC-containing products represented as dietary supplements have been sold in the United States for more than 30 years, the agency said, and consumers continue to seek access to them. In August 2022, the FDA issued final guidance stating its intent to exercise temporary enforcement discretion for certain NAC products labeled as dietary supplements, and the agency said that policy will continue while the rulemaking process proceeds.
The FDA said the action, if finalized, would be a deregulatory action under President Trump's Executive Order 14192, "Unleashing Prosperity Through Deregulation." Details on how to submit a comment are in the Federal Register notice.
(Source: U.S. Food and Drug Administration)
来源:美国食品药品监管局
发布:GSM·美国(发布链接)
图片来源:图:美国食品药品监管局总部大楼。美国食品药品监管局官方照片,公共领域。 / Photo: Headquarters of the U.S. Food and Drug Administration. U.S. Food and Drug Administration photo, public domain.
GSM Global · 本篇英文版 English edition of this story

